FDA panel deals blow to Sanofi obesity drug (Financial Times)
Sanofi-Aventis was the latest drugmaker to suffer a blow from heightened US drug safety concerns Wednesday as a regulatory panel recommended that its obesity drug Acomplia not be approved.

CEL-SCI Receives US FDA Orphan Drug Designation For Its Cancer Drug Multikine(R) (Medical News Today)
CEL-SCI Corporation (Amex: CVM) announced today that its cancer drug Multikine(R) has been granted orphan-drug designation as neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (head and neck cancer) by the United States Food and Drug Administration (FDA). [click link for full article]

Zydus Cadila gets US FDA marketing nod for 3 drugs (PharmaBiz)
Zydus Cadila has received three product approvals from the US FDA in quick succession. The group has received approvals to market benzonatate tablets 100 and 200 mg, naproxen tablets and tentative approval for amlodipine besylate tablets 2.5, 5 and 10 mg.